Annual report
4671.TEDINET S100YS5W
Period2025-04-01 → 2026-03-31
Filed2026-07-24
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Amends S100YIIX. Amended by S100YS61 (2026-07-24).
Key figures · 158
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥43.6bn | 2025-04-01 → 2026-03-31 | Cons. | Net sales |
| Revenue | ¥43.3bn | 2024-04-01 → 2025-03-31 | Cons. | Net sales |
| Revenue | ¥43.0bn | 2023-04-01 → 2024-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥46.9bn | 2022-04-01 → 2023-03-31v | Cons. | Net sales (5-year summary) |
| Revenue | ¥50.0bn | 2021-04-01 → 2022-03-31v | Cons. | Net sales (5-year summary) |
| Operating income | ¥2.5bn | 2025-04-01 → 2026-03-31 | Cons. | Operating income |
| Operating income | ¥2.3bn | 2024-04-01 → 2025-03-31 | Cons. | Operating income |
| Ordinary income | ¥2.7bn | 2025-04-01 → 2026-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.5bn | 2024-04-01 → 2025-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥2.3bn | 2023-04-01 → 2024-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥3.3bn | 2022-04-01 → 2023-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥5.8bn | 2021-04-01 → 2022-03-31v | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥3.1bn | 2025-04-01 → 2026-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥2.8bn | 2024-04-01 → 2025-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥2.0bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥1.7bn | 2023-04-01 → 2024-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥2.3bn | 2022-04-01 → 2023-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥3.5bn | 2021-04-01 → 2022-03-31v | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥2.0bn | 2025-04-01 → 2026-03-31 | Cons. | Profit loss |
| Net income | ¥1.9bn | 2024-04-01 → 2025-03-31 | Cons. | Profit loss |
| Total assets | ¥36.9bn | at 2026-03-31 | Cons. | Assets |
| Total assets | ¥36.0bn | at 2025-03-31 | Cons. | Assets |
| Total assets | ¥36.4bn | at 2024-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥38.9bn | at 2023-03-31v | Cons. | Total assets (5-year summary) |
| Total assets | ¥40.3bn | at 2022-03-31v | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥11.0bn | at 2026-03-31 | Cons. | Liabilities |
| Total liabilities | ¥10.8bn | at 2025-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥25.9bn | at 2026-03-31 | Cons. | Net assets |
| Net assets / equity | ¥25.3bn | at 2025-03-31 | Cons. | Net assets |
| Net assets / equity | ¥26.0bn | at 2024-03-31v | Cons. | Net assets |
| Net assets / equity | ¥26.6bn | at 2023-03-31v | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥23.5bn | at 2022-03-31v | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥9.3bn | at 2026-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥9.4bn | at 2025-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥8.3bn | at 2026-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥9.4bn | at 2025-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥10.1bn | at 2024-03-31v | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥12.6bn | at 2023-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥10.6bn | at 2022-03-31v | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥2.9bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥2.6bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥3.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥2.1bn | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥4.1bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥2.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.2bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥1.4bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | ¥322m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥2.7bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | −¥2.0bn | 2025-04-01 → 2026-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥2.1bn | 2024-04-01 → 2025-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.5bn | 2023-04-01 → 2024-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥448m | 2022-04-01 → 2023-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥2.4bn | 2021-04-01 → 2022-03-31v | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥201.1 | 2025-04-01 → 2026-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥181.81 | 2024-04-01 → 2025-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥151.72 | 2023-04-01 → 2024-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥215.29 | 2022-04-01 → 2023-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥339 | 2021-04-01 → 2022-03-31v | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥200.06 | 2025-04-01 → 2026-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥180.81 | 2024-04-01 → 2025-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥150.9 | 2023-04-01 → 2024-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥214.03 | 2022-04-01 → 2023-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥336.99 | 2021-04-01 → 2022-03-31v | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥2,577.71 | at 2026-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,479.62 | at 2025-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,431.22 | at 2024-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,362.21 | at 2023-03-31v | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥2,237.14 | at 2022-03-31v | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 70.0% | at 2026-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 69.9% | at 2025-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 71.2% | at 2024-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 68.2% | at 2023-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 58.1% | at 2022-03-31v | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.9% | 2025-04-01 → 2026-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.5% | 2024-04-01 → 2025-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 6.4% | 2023-04-01 → 2024-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.1% | 2022-04-01 → 2023-03-31v | Cons. | Rate of return on equity (5-year summary) |
| ROE | 16.1% | 2021-04-01 → 2022-03-31v | Cons. | Rate of return on equity (5-year summary) |
| Employees | 1,037 | at 2026-03-31 | Cons. | Number of employees |
| Employees | 1,062 | at 2025-03-31 | Cons. | Number of employees |
| Employees | 1,117 | at 2024-03-31v | Cons. | Number of employees |
| Employees | 1,159 | at 2023-03-31v | Cons. | Number of employees |
| Employees | 1,179 | at 2022-03-31v | Cons. | Number of employees |
| Revenue | ¥3.3bn | 2025-04-01 → 2026-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.4bn | 2024-04-01 → 2025-03-31 | Standalone | Operating revenue1 |
| Revenue | ¥3.0bn | 2023-04-01 → 2024-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥3.4bn | 2022-04-01 → 2023-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Revenue | ¥3.8bn | 2021-04-01 → 2022-03-31v | Standalone | Operating revenue1 (5-year summary) |
| Operating income | ¥1.5bn | 2025-04-01 → 2026-03-31 | Standalone | Operating income |
| Operating income | ¥1.7bn | 2024-04-01 → 2025-03-31 | Standalone | Operating income |
| Ordinary income | ¥1.6bn | 2025-04-01 → 2026-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.8bn | 2024-04-01 → 2025-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥1.5bn | 2023-04-01 → 2024-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥1.9bn | 2022-04-01 → 2023-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥2.8bn | 2021-04-01 → 2022-03-31v | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥2.0bn | 2025-04-01 → 2026-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Income before income taxes |
| Net income | ¥2.0bn | 2025-04-01 → 2026-03-31 | Standalone | Profit loss |
| Net income | ¥2.2bn | 2024-04-01 → 2025-03-31 | Standalone | Profit loss |
| Net income | ¥1.9bn | 2023-04-01 → 2024-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.3bn | 2022-04-01 → 2023-03-31v | Standalone | Net income loss (5-year summary) |
| Net income | ¥2.6bn | 2021-04-01 → 2022-03-31v | Standalone | Net income loss (5-year summary) |
| Total assets | ¥24.9bn | at 2026-03-31 | Standalone | Assets |
| Total assets | ¥24.4bn | at 2025-03-31 | Standalone | Assets |
| Total assets | ¥24.2bn | at 2024-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥26.4bn | at 2023-03-31v | Standalone | Total assets (5-year summary) |
| Total assets | ¥24.3bn | at 2022-03-31v | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥1.9bn | at 2026-03-31 | Standalone | Liabilities |
| Total liabilities | ¥2.0bn | at 2025-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥23.0bn | at 2026-03-31 | Standalone | Net assets |
| Net assets / equity | ¥22.4bn | at 2025-03-31 | Standalone | Net assets |
| Net assets / equity | ¥22.9bn | at 2024-03-31v | Standalone | Net assets |
| Net assets / equity | ¥23.2bn | at 2023-03-31v | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥20.1bn | at 2022-03-31v | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.2bn | at 2026-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.1bn | at 2025-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥198.15 | 2025-04-01 → 2026-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥205.29 | 2024-04-01 → 2025-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥171.85 | 2023-04-01 → 2024-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥218.04 | 2022-04-01 → 2023-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥254.07 | 2021-04-01 → 2022-03-31v | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥197.13 | 2025-04-01 → 2026-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥204.17 | 2024-04-01 → 2025-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥170.92 | 2023-04-01 → 2024-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥216.76 | 2022-04-01 → 2023-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥252.56 | 2021-04-01 → 2022-03-31v | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥125 | 2025-04-01 → 2026-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥123 | 2024-04-01 → 2025-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥115 | 2023-04-01 → 2024-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥100 | 2022-04-01 → 2023-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥64 | 2021-04-01 → 2022-03-31v | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥2,287.06 | at 2026-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,196.19 | at 2025-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,138.28 | at 2024-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥2,063.91 | at 2023-03-31v | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,914.28 | at 2022-03-31v | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 92.0% | at 2026-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 91.3% | at 2025-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 94.3% | at 2024-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 87.8% | at 2023-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 82.4% | at 2022-03-31v | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 8.8% | 2025-04-01 → 2026-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 9.6% | 2024-04-01 → 2025-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 8.2% | 2023-04-01 → 2024-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 10.6% | 2022-04-01 → 2023-03-31v | Standalone | Rate of return on equity (5-year summary) |
| ROE | 14.0% | 2021-04-01 → 2022-03-31v | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 10,680,177 | at 2026-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 10,880,177 | at 2025-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,080,177 | at 2024-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2023-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 11,280,177 | at 2022-03-31v | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4 | at 2026-03-31 | Standalone | Number of employees |
| Employees | 3 | at 2025-03-31 | Standalone | Number of employees |
| Employees | 4 | at 2024-03-31v | Standalone | Number of employees |
| Employees | 4 | at 2023-03-31v | Standalone | Number of employees |
| Employees | 3 | at 2022-03-31v | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 69
| Segment | Item | Period | Value |
|---|---|---|---|
| Reconciling Itemsreconciling | capex | 2025-04-01 → 2026-03-31 | ¥803m |
| Reconciling Itemsreconciling | depreciation | 2025-04-01 → 2026-03-31 | ¥286m |
| Reconciling Itemsreconciling | revenue | 2025-04-01 → 2026-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2025-04-01 → 2026-03-31 | −¥1m |
| Reconciling Itemsreconciling | segment assets | at 2026-03-31 | ¥21.6bn |
| Reconciling Itemsreconciling | segment profit | 2025-04-01 → 2026-03-31 | −¥450m |
| Clinical Testing Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥728m |
| Clinical Testing Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥575m |
| Clinical Testing Businessreportable segment | employees | at 2026-03-31 | 570 pure |
| Clinical Testing Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥26.7bn |
| Clinical Testing Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥26.7bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥0 |
| Clinical Testing Businessreportable segment | segment assets | at 2026-03-31 | ¥9.3bn |
| Clinical Testing Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥1.8bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥185m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥121m |
| Dispensing Pharmacy Businessreportable segment | employees | at 2026-03-31 | 373 pure |
| Dispensing Pharmacy Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥15.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥15.2bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2026-03-31 | ¥5.0bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥674m |
| ICT Businessreportable segment | capex | 2025-04-01 → 2026-03-31 | ¥165m |
| ICT Businessreportable segment | depreciation | 2025-04-01 → 2026-03-31 | ¥77m |
| ICT Businessreportable segment | employees | at 2026-03-31 | 71 pure |
| ICT Businessreportable segment | revenue | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| ICT Businessreportable segment | revenue external | 2025-04-01 → 2026-03-31 | ¥1.7bn |
| ICT Businessreportable segment | segment assets | at 2026-03-31 | ¥931m |
| ICT Businessreportable segment | segment profit | 2025-04-01 → 2026-03-31 | ¥458m |
| —segment total | capex | 2025-04-01 → 2026-03-31 | ¥1.1bn |
| —segment total | depreciation | 2025-04-01 → 2026-03-31 | ¥774m |
| —segment total | revenue | 2025-04-01 → 2026-03-31 | ¥43.6bn |
| —segment total | revenue external | 2025-04-01 → 2026-03-31 | ¥43.6bn |
| —segment total | revenue intersegment | 2025-04-01 → 2026-03-31 | ¥1m |
| —segment total | segment assets | at 2026-03-31 | ¥15.3bn |
| —segment total | segment profit | 2025-04-01 → 2026-03-31 | ¥2.9bn |
| Reconciling Itemsreconciling | capex | 2024-04-01 → 2025-03-31 | ¥618m |
| Reconciling Itemsreconciling | depreciation | 2024-04-01 → 2025-03-31 | ¥250m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2025-03-31 | −¥1m |
| Reconciling Itemsreconciling | segment assets | at 2025-03-31 | ¥20.7bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2025-03-31 | −¥429m |
| Clinical Testing Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥624m |
| Clinical Testing Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥513m |
| Clinical Testing Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥26.4bn |
| Clinical Testing Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥26.4bn |
| Clinical Testing Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥0 |
| Clinical Testing Businessreportable segment | segment assets | at 2025-03-31 | ¥9.5bn |
| Clinical Testing Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥1.6bn |
| Dispensing Pharmacy Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥143m |
| Dispensing Pharmacy Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥116m |
| Dispensing Pharmacy Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥15.5bn |
| Dispensing Pharmacy Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥15.5bn |
| Dispensing Pharmacy Businessreportable segment | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| Dispensing Pharmacy Businessreportable segment | segment assets | at 2025-03-31 | ¥5.0bn |
| Dispensing Pharmacy Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥816m |
| ICT Businessreportable segment | capex | 2024-04-01 → 2025-03-31 | ¥133m |
| ICT Businessreportable segment | depreciation | 2024-04-01 → 2025-03-31 | ¥54m |
| ICT Businessreportable segment | revenue | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| ICT Businessreportable segment | revenue external | 2024-04-01 → 2025-03-31 | ¥1.5bn |
| ICT Businessreportable segment | segment assets | at 2025-03-31 | ¥842m |
| ICT Businessreportable segment | segment profit | 2024-04-01 → 2025-03-31 | ¥353m |
| —segment total | capex | 2024-04-01 → 2025-03-31 | ¥901m |
| —segment total | depreciation | 2024-04-01 → 2025-03-31 | ¥685m |
| —segment total | revenue | 2024-04-01 → 2025-03-31 | ¥43.3bn |
| —segment total | revenue external | 2024-04-01 → 2025-03-31 | ¥43.3bn |
| —segment total | revenue intersegment | 2024-04-01 → 2025-03-31 | ¥1m |
| —segment total | segment assets | at 2025-03-31 | ¥15.3bn |
| —segment total | segment profit | 2024-04-01 → 2025-03-31 | ¥2.8bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 1,599
| Item | Context | Value | Unit |
|---|---|---|---|
| Independent auditors report consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 consolidated | FilingDateInstant | Original text (Japanese)太陽有限責任監査法人 | |
| Cpa1 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)大好 慧 | |
| Cpa2 audit firm1 consolidated | FilingDateInstant | Original text (Japanese)山内 紀彰 | |
| Audit opinion consolidated (text) | FilingDateInstant | Text · Plus | |
| Key audit matters consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam consolidated (text) | FilingDateInstant | Text · Plus | |
| Short description kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)調剤薬局事業における固定資産の減損損失の認識の判定の妥当性 | |
| Description including reason kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Reference kam consolidated | FilingDateInstant_Row1Member | Original text (Japanese)【注記事項】（重要な会計上の見積り） | |
| Auditors response kam consolidated (text) | FilingDateInstant_Row1Member | Text · Plus | |
| Other information consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information consolidated (text) | FilingDateInstant | Text · Plus | |
| Independent auditors report non consolidated (text) | FilingDateInstant | Text · Plus | |
| Audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)太陽有限責任監査法人 | |
| Cpa1 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)大好 慧 | |
| Cpa2 audit firm1 non consolidated | FilingDateInstant | Original text (Japanese)山内 紀彰 | |
| Audit opinion non consolidated (text) | FilingDateInstant | Text · Plus | |
| Key audit matters non consolidated (text) | FilingDateInstant | Text · Plus | |
| Overview kam non consolidated (text) | FilingDateInstant | Text · Plus | |
| Other information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Fee related information non consolidated (text) | FilingDateInstant | Text · Plus | |
| Number of submission | FilingDateInstant | 2 | |
| Net sales (5-year summary) | Prior4YearDuration | 50007000000 | JPY |
| Net sales (5-year summary) | Prior3YearDuration | 46913000000 | JPY |
| Net sales (5-year summary) | Prior2YearDuration | 43007000000 | JPY |
| Net sales (5-year summary) | Prior1YearDuration | 43313000000 | JPY |
| Net sales (5-year summary) | CurrentYearDuration | 43578000000 | JPY |
| Ordinary income loss (5-year summary) | Prior4YearDuration | 5809000000 | JPY |
| Ordinary income loss (5-year summary) | Prior3YearDuration | 3310000000 | JPY |
| Ordinary income loss (5-year summary) | Prior2YearDuration | 2288000000 | JPY |
| Ordinary income loss (5-year summary) | Prior1YearDuration | 2499000000 | JPY |
| Ordinary income loss (5-year summary) | CurrentYearDuration | 2689000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior4YearDuration | 3533000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior3YearDuration | 2261000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior2YearDuration | 1666000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | Prior1YearDuration | 1920000000 | JPY |
| Profit loss attributable to owners of parent (5-year summary) | CurrentYearDuration | 2016000000 | JPY |
| Comprehensive income (5-year summary) | Prior4YearDuration | 3468000000 | JPY |
| Comprehensive income (5-year summary) | Prior3YearDuration | 2296000000 | JPY |
| Comprehensive income (5-year summary) | Prior2YearDuration | 1773000000 | JPY |
| Comprehensive income (5-year summary) | Prior1YearDuration | 1881000000 | JPY |
| Comprehensive income (5-year summary) | CurrentYearDuration | 2252000000 | JPY |
| Net assets (5-year summary) | Prior4YearInstant | 23478000000 | JPY |
| Net assets (5-year summary) | Prior3YearInstant | 26591000000 | JPY |
| Net assets (5-year summary) | Prior2YearInstant | 26026000000 | JPY |
| Net assets (5-year summary) | Prior1YearInstant | 25253000000 | JPY |
| Net assets (5-year summary) | CurrentYearInstant | 25869000000 | JPY |
| Total assets (5-year summary) | Prior4YearInstant | 40256000000 | JPY |
| Total assets (5-year summary) | Prior3YearInstant | 38893000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |